Abstract
The lactogenic hormone prolactin is produced in part by cells of the immune system and serves as an upregulator of immune function. Hyperprolactinemia is common in patients with systemic lupus erythematosus (SLE), raising the possibility that the hormone contributes to the excessive immune response in the disease. The highest levels of circulating prolactin occur in association with prolactin-secreting tumors, but prolactinomas have only rarely been encountered in patients with SLE. We present here three patients with SLE and prolactinomas. As with the previously reported six patients, there was no consistency in the presence of findings related to prolactin excess or in the coincidence of hyperprolactinemia with flares of SLE disease activity. We speculate that this may be due to genetic differences in the response to prolactin and/or to the presence of variant prolactin isoforms detected in the clinical immunoassay that have reduced or absent biologic activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Schlechte J (2003) Prolactinoma. N Engl J Med 349:2035–2041
Peeva E, Venkatesh J, Michael D, Diamond B (2004) Prolactin as a modulator of B cell function; implications for SLE. Biomed Pharmacother 58:310–319
Lahita R (1999) The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol 11:352–356
Funauchi M, Ikoma S, Enomoto H, Sugiyama M, Ohno M, Hamada K, Kanamaru A (1998) Prolactin modulates the disease activity of systemic lupus erythematosus accompanied by prolactinoma. Clin Exp Rheumatol 16:479–482
McMurray R, Allen SH, Braun AL, Rodriguez F, Walker SE (1994) Longstanding hyperprolactinemia associated with systemic lupus erythematosus: possible hormonal stimulation of an autoimmune disease. J Rheumatol 21:843–850
Reuman P (2004) First reported pediatric case of systemic lupus erythematosus associated with prolactinoma. Arthritis Rheum 50:3616–3618
Chikanza I (1999) Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Ann N Y Acad Sci 876:119–130
McMurray R et al (1991) Prolactin influences autoimmune disease activity in the female NZB/W mouse. J Immunol 147:3780–3787
McMurray R, Keisler D, Izui S, Walker S (1994) Hyperprolactinemia in male NZB/NZW (B/W) F1 mice: accelerated autoimmune disease with normal circulating testosterone. Clin Immunol Immunopathol 71:338–343
Peeva E, Michael D, Cleary J, Rice J, Chen X, Diamond B (2003) Prolactin modulates the naive B cell repertoire. J Clin Invest 111:275–283
Kanda N, Tsuchida T, Tamaki K (1999) Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 42:328–337
McMurray R et al (1995) Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol 22:2084–2091
Guitelman M, Colombani-Vidal ME, Zylbersztein CC, Fiszlejder L, Zeller M, Levalle O, Scaglia HE (2002) Hyperprolactinemia in asymptomatic patients is related to high molecular weight posttranslational variants or glycosylated forms. Pituitary 5:255–260
Leanos-Miranda A, Chavez-Rueda K, Blanco-Favela F (2001) Biologic activity and plasma clearance of prolactin-IgG complex in patients with systemic lupus erythematosus. Arthritis Rheum 44:866–875
Acknowledgements
The authors would like to thank Dr. Peter Barland, Dr. Meggan Mackay, and Dr. Arielle Silver for supplying the cases; Dr. Joaquim M. Farinhas for expert radiology help; and Dr. Betty Diamond for critical reading of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, M., Keiser, H.D. & Peeva, E. Prolactinoma and systemic lupus erythematosus: do serum prolactin levels matter?. Clin Rheumatol 25, 602–605 (2006). https://doi.org/10.1007/s10067-005-0117-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-005-0117-x